{
    "Trade/Device Name(s)": [
        "INNOVANCE\u00ae D-Dimer"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Products GmbH",
    "510(k) Number": "K091916",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040882"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DAP"
    ],
    "Summary Letter Date": "October 28, 2009",
    "Summary Letter Received Date": "October 29, 2009",
    "Submission Date": "September 22, 2009",
    "Regulation Number(s)": [
        "21 CFR 864.7320"
    ],
    "Regulation Name(s)": [
        "Fibrinogen/fibrin degradation product assays"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "D-dimer",
        "cross-linked fibrin degradation products"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Siemens Healthcare Diagnostics Coagulation Systems",
        "Sysmex\u00ae Coagulation Systems",
        "BCS",
        "BCS XP System"
    ],
    "Method(s)/Technology(ies)": [
        "Turbidimetric immunoassay"
    ],
    "Methodologies": [
        "Antigen-antibody aggregation",
        "Turbidimetric detection"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for INNOVANCE D-Dimer turbidimetric immunoassay for detection of D-dimer in plasma to aid in exclusion of PE and diagnosis of VTE.",
    "Indications for Use Summary": "For quantitative determination of cross-linked fibrin degradation products (D-dimers) in human plasma to exclude pulmonary embolism and aid in diagnosing venous thromboembolism, when used with a non-high clinical pretest probability assessment model.",
    "fda_folder": "Hematology"
}